SILENCE THERAPEUTICS ORD 5P news, videos and press releases
For more news please use our advanced search feature.
SILENCE THERAPEUTICS ORD 5P - More news...
SILENCE THERAPEUTICS ORD 5P - More news...
- Silence Therapeutics Reports Second Quarter 2023 Results
- Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
- Silence Therapeutics to Present at the Jefferies Healthcare Conference
- Silence Therapeutics Reports First Quarter 2023 Results
- Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
- Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
- Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
- Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
- Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
- Silence Therapeutics to Buyback siRNA Complement Assets
- Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
- Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
- Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
- Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
- Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
- Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Silence Therapeutics Reports Third Quarter 2022 Results
- Silence Therapeutics to Present at Jefferies London Healthcare Conference
- Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
- Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
- Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
- Silence Therapeutics to Participate in September Investment Conferences
- Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
- Silence Therapeutics Announces Pricing of Underwritten Offering
- Silence Therapeutics to Present at Jefferies Healthcare Conference
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
- Silence Therapeutics Reports First Quarter 2022 Results
- Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
- Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
